Factors associated with response to filgotinib and the prognostic power of faecal calprotectin for ulcerative colitis in the phase 2b/3 SELECTION trial.

Date publication

mai 2025

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Louis E, Schreiber S, Hisamatsu T, Hibi T, Jamoul C, Muller K, Taliadouros V, Oortwijn A, Peyrin-Biroulet L, Feagan BG

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40379541

Résumé

Patients with moderately to severely active ulcerative colitis have distinct filgotinib response trajectories.

Mots clés

Filgotinib, Partial Mayo Clinic Score, Treatment response, Treatment trajectory

Référence

Dig Liver Dis. 2025 05 15;: